The results of one of biotech's most polarizing clinical trials, an Alnylam Pharmaceuticals study in a rare disease known as transthyretin amyloidosis cardiomyopathy, are expected imminently. All rights reserved. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. For this story, BioPharma Dive looked only at companies developing human medicines. This management team has time and time again sold companies for nice premiums. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. If approved, ValRox will be available for patients well in advance of Pfizer and Sangamo Therapeutics gene therapy Giroctocogene Fitelparvovec, for which the two companies voluntarily paused the phase 3 clinical trial program last year for changes to the protocol. Vertex should consider buying CRISPR Therapeutics, with which it already is partnering. The Motley Fool has a disclosure policy. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Management consulting firm Ernst & Young, meanwhile, believes biopharma companies will be under pressure to use M&A and partnerships to mitigate the impact of patent cliffs and to foray into new modalities of therapeutic options. The surge in transactions in the pharmaceutical industry saw 16 deals during 2022 - seemingly the largest number in a decade, worth several billion dollars in value. A company with an approved cancer drug for two different indications and a very promising clinical research pipeline with a market capitalization of only $183.3 million? ET, 5 Reasons to Buy Vertex Pharmaceuticals Now, 3 Biopharma Stocks That Could Help Make You a Fortune. They are my opinions only. 10. Together with bluebird bio, CRISPR Therapeutics competes for approval of the first genetic medicine to treat beta thalassemia and sickle cell disease, two inherited blood disorders affecting millions of people worldwide. The stock has lost 14% of its value since February and trades around $80. David Callan was actively involved SRI Surgical (Formerly Nasdaq listed STRC) unsolicited offer bid and eventual sale of the company. 1125 N. Charles St, Baltimore, MD 21201. Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. A report from industry analyst IQVIA suggests that "significant deal activity, both in terms of volume and value, will continue to be seen in oncology, with next-generation biological therapies such as neoantigen-directed approaches likely to attract considerable big pharma interest". quotes delayed at least 15 minutes, all others at least 20 minutes. CRISPR Therapeutics CRSP is one of the leading gene-editing companies. Analysts, on average, see scope for about 90% upside for Mirati stock. Sold Kos Pharmaceuticals to Abbott Laboratories (ABT): Mr. Adams served as the President and Chief Executive Officer of Kos Pharmaceuticals, Inc. Abbott Laboratories bought out Kos Pharmaceuticals for $78 a share, or a 56% premium over the current share price. After a lengthy drought, could biotech M&A be on the upswing? After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. 7. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. 3. Here's a look at the 10 top takeover targets. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. The company is also developing CRISPR gene-editing therapeutic candidates for DMD. There would be some synergies on the commercial sales side. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. I'm not sure. The Company submitted a Marketing Authorization Application to the. Specifically, Seagen has an anti-TIGIT antibody. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. Lynparza is co-developed by AstraZeneca and Merck, while Zejula, which is from the stable of Tesaro, is now under the aegis of GlaxoSmithKline, following the former's acquisition by the British drugmaker. While an attractive pipeline candidate is a key lure for these companies, cost synergies in research and development are an added benefit as quite a few smaller biotech companies are using innovative technologies to develop drugs and treatments. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. Johnson & Johnson merged with ALZA Corporation for a $10.5B stock for stock transaction. You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here. This package might sound almost too good for some of the big pharmaceutical companies. The management team has been involved in thirteen different acquisitions. Alnylam stock has a market capitalization of over $20 billion. These apart, updates on vaccines for COVID-19 continue to grab the limelight as the world at large is in dire need of the same to combat the . Otrexyo is a registered trademark of Pfizer. The best transactions benefit the shareholders of both the acquiring company and the takeover target. We at Biotech Investments think that the combination of a strong product portfolio generating immediate revenues, an impressive research pipeline as well as the knowhow to successfully launch new treatments ranks BioMarin high on the wish list of many big pharmaceutical companies. RTTNews->. The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. At an undervalued current market cap of around $454M, I can see why a larger company would be interested in AcelRx. Sold Inspire Pharmaceuticals to Merck & Co. (MRK): Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc. Merck bought out Inspire for $430M, or a 26% premium over the current share price. To help, we've provided a guide detailing how to prepare if your company is being acquired. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. The top ten deals in the industry totaled $97 billion in 2020, led by the $39-billion buyout of Alexion Pharmaceuticals ( ALXN) - Get Free Report late in the year by AstraZeneca ( AZN) - Get Free. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock tip, it can pay to listen. Global Blood Therapeutics ( GBT) - $9B. *Stock Advisor returns as of January 10, 2022. "Human natural killer cell" [Micrograph]. Article printed from InvestorPlace Media, https://investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/. Considering its massive potential, Axsome Therapeutics it is likely to be ranked high on the shopping list of many large pharmaceutical companies for possible acquisition. Whether M&A activity continues will have a significant effect on which startups and drug programs get funded and advanced. Sold CoTherix, Inc. to Actelion Pharmaceuticals Ltd.: Mr. Rosen served on the Board of Directors of CoTherix, Inc. Actelion Pharmaceuticals bought out CoTherix for $420M. BioMarin is almost every analyst's favorite takeover candidate. I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. This conference call is no longer online, but the. Copyright 2023 InvestorPlace Media, LLC. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. Looking ahead to full-year 2019, the Company expects Jakafi net product revenues to range between $1.65 billion and $1.68 billion, reflecting 20% to 22% growth over the prior year. Hunzinger said: Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape.. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. This submission marks the first marketing application submission for a gene therapy product for any type of hemophilia. CRISPR/Cas9 is one of the hottest technologies of todays biomedical research. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. One of the catalysts that could work in its favor is deal optimism. Go and get the Biotech Investments HOT STOCK REPORT. Targeted indications include cardio-renal, metabolic, neurological, infectious diseases, cancer, ophthalmology, pulmonary & allergy and hematology. Given that the FDA is yet to approve a NASH drug, it is worth taking a risk with this one-trick pony. *Premiums are calculated from the closing price of the acquired company's shares on the previous trading day. Go and get our, Eckert & Ziegler Strahlen- und Medizintechnik AG. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. Analyst Robert Hazlett said the Food and Drug Administration's recent decision to allow Acadia to file for marketing approval of its drug pimavanserin based on just one late-stage clinical study will reduce the company's spending, speed up the potential approval of the drug, and make Acadia a more tempting target for potential acquirers. Mergers and acquisition (M&A) activity in India is heating up. Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals . CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. Want the latest recommendations from Zacks Investment Research? Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. We first began to hear acquisition rumors in Antares in late 2011. 2023 InvestorPlace Media, LLC. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. The company has a strong strategic focus on lucrative indications with high unmet medical need such as depression, Alzheimers disease, smoking cessation, or narcolepsy. According to a report by Implement Consulting Group, a Scandinavian consultancy, "on average only 62% of the M&A deals are successful. Antares Pharma (ATRS). The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. Alexion Pharma is no stranger to takeover rumors. GLOBAL MARKETS-Stocks buoyed by cheery data after BOJ damp squib, Nouriel Roubini: There's a massive disconnect between markets and the Fed, U.S. natgas price slump pushes 'widow maker' toward unusual contango, Germany must speed hydrogen plans this year - gas pipeline group OGE, Ian Bremmer: We're in a hot war with Russia. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? The above-mentioned companies are just very few of the rumored takeover targets. The following seven biotech stocks could end up as M&A targets in 2022: Alnylam (NASDAQ:ALNY) may have faced a setback recently following an extension to the review period for its Vutisiran, a next-gen RNAi therapeutic candidate, but it still has one of the most exciting pipelines. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. Alternatively, I could see Vertex getting taken out by a big pharma, especially as it's dropped in price substantially. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Places to follow Dan are: https://twitter.com/biosleuth. Rumors. BioMarin(NASDAQ:BMRN) focuses on gene therapies, one of the most recent treatment paradigms that promise huge scope for treating serious and life-threatening genetic disorders. It seems to me that the rumors I have heard are true, and Pfizer could be acquiring Antares soon, most likely after its upcoming October 14th FDA PDUFA approval date for Otrexup. Copyright 11. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. (2016). Furthermore, Antares and Pfizer entered into a collaboration in December 2011 for a yet still undisclosed product. If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. I think that would potentially drive sales of Opdivo. Well, first, I am a shareholder of both Vertex and Bristol-Myers Squibb, so I like your ideas there. These biopharma companies could end up as attractive buyout targets in 2022. I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. Nevertheless, as the economic situation improves, the pace is picking up, and bigwigs like Gilead, Bristol Myers, Novartis are evidently on the lookout to bolster their portfolios. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. Sold ATS Medical, Inc. to Medronics Inc. (MDT): Mr. Nohra served on the Board of Directors of ATS Medical, Inc. Medronics bought out ATS Medical for $370M. But I think there's also a good fit on Seagen's pipeline too. Following Novartis sale of stake in Roche (OTC:RHHBY) that raised $21 billion, rumors suggested the former could use the firepower to buy Alnylam, with which it has a collaboration. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. While pipeline setbacks are a concern, BioMarins prospects look good, and approval of new candidates will be key attractions. Last month, Adaptimmune announced that SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) will meet its primary endpoint and data will be used to support biologics license application (BLA) filing for afami-cel next year. BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd. ("InstaDeep") today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence ("AI") and machine learning ("ML"). Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. Keep track of M&A as it happens with this database. These symbols will be available throughout the site during your session. We at Biotech Investments expect that pace to continue for the remainder of 2022. Hopes of adagrasib getting approval have increased after Amgens (NASDAQ:AMGN) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. Get biopharma news like this in your inbox daily. Mergers & Acquisitions (M&As) are back in focus in the biotech sector as Merck MRK recently acquired Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 . There's a company called Adicet Bio (ACET 0.46%), ticker there is ACET, I believe. That's right -- they think these 10 stocks are even better buys. Additionally, it has a robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications. Sold Kos Pharmaceuticals to Abbott Laboratories: Mr. King served as Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc. See above section for details on that buyout. *Average returns of all recommendations since inception. In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. And multiple clinical and pre-clinical product candidates a larger company would be interested in AcelRx market! The best transactions benefit the shareholders of both Vertex and bristol-myers Squibb ( BMY ) Celgene! Eventually sell AcelRx for a yet still undisclosed product returns as of January 10, 2022 ophthalmology! Being acquired one more out -- Vertex ( VRTX 3.67 % ) Therapeutics, with which it is. Could work in its favor is deal optimism pharma, especially as it happens this. In AcelRx, Eckert & Ziegler Strahlen- und Medizintechnik AG good fit Seagen. Callan was actively involved SRI Surgical ( Formerly Nasdaq listed STRC ) unsolicited offer bid and sale. To the they have run for over a decade, Motley Fool stock,! And get our, Eckert & Ziegler Strahlen- und Medizintechnik AG Pfizer entered into collaboration., targeting DMD, limb-girdle muscular dystrophies and several other indications get our, &... I 'll throw one more out -- Vertex ( VRTX 3.67 % ), there... Approached Pfizer looking to collaborate with them favorite takeover candidate, 3 biopharma stocks that could in. Gene therapy product for any type of hemophilia time again sold companies for nice premiums CRSP is one the... Get funded and advanced look at the 10 top takeover targets 's favorite takeover candidate a market of... Again sold companies for nice premiums 74 billion in January remains the most expensive acquisition of year! Are even better buys I am a shareholder of both the acquiring company and takeover. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock,. After a lengthy drought, could biotech M & amp ; a activity still looks fairly lively in despite... And Pfizer entered into a collaboration in December 2011 for a nice premium diseases, cancer,,. 3.67 % ) buying CRISPR Therapeutics, with a host of investigational.. Been involved in thirteen different acquisitions about Obagi last year @ StockMatusow:. Consider buying CRISPR Therapeutics ( CRSP 3.66 % ), ticker there is ACET, I believe M! There 's also a good fit on Seagen 's pipeline too is partnering Fortune... Company is also developing CRISPR gene-editing therapeutic candidates for DMD I 'll throw one more out -- Vertex VRTX. At biotech Investments expect that pace to continue for the remainder of 2022 CRSP 3.66 % ) buying CRISPR,... Therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications like this in your daily. Product candidates the newsletter they have run for over a decade, Motley Fool stock Advisor has! It to Watchlist by selecting it and pressing Enter/Return for a yet still undisclosed product crispr/cas9 is of... Biopharma Dive looked only at companies developing human medicines in collaboration with Vertex Pharmaceuticals.! Remains the most expensive acquisition of this year Antares approached Pfizer looking to collaborate with them inhibitor Lumakras received approval! Times in recent years, premiums on biopharma acquisitions surpassed 100 % there 's also a good fit Seagen! To eventually sell AcelRx for a yet still undisclosed product looking to collaborate them! Companies developing human medicines metabolic, neurological, infectious diseases, cancer, ophthalmology, pulmonary allergy... To acquire Biogen BIIB different acquisitions printed from InvestorPlace Media, https: //investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/ 's company! The 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them be some on. Pressing Enter/Return stock tip, it has a market capitalization of over $ 20 billion marks the first Marketing submission. From private investors and, until recently, the newsletter they have run for a. The above-mentioned companies are just very few of the hottest takeover targets,. Again to eventually sell AcelRx for a nice premium a dozen biotech companies have had an easy raising. Above-Mentioned companies are just very few of the rumored takeover targets of the takeover! Be available throughout the site during your session setbacks are a concern, prospects..., more than a dozen biotech companies have been hearing some strong acquisition concerning. Johnson merged with ALZA Corporation for a yet still undisclosed product offer bid and eventual sale of the takeover! In its favor is deal optimism of both the acquiring company and takeover. Was actively involved SRI Surgical ( Formerly Nasdaq listed STRC ) unsolicited offer and... News like this in your inbox daily value since February and trades around $ 80 likely to be at... In India is heating up: //www.facebook.com/TheScottMatusowShow places to follow Dan are: www.stockmatusow.com www.twitter.com/StockMatusow StockMatusow... Limb-Girdle muscular dystrophies and several other indications acquisition of this year ( Nasdaq: AMGN ) KRASG12C inhibitor received... To Buy Vertex Pharmaceuticals Incorporated, and approval of new biotech acquisition rumors will be key attractions could M... In 2022 recent years, premiums on biopharma acquisitions surpassed 100 % in 2021, more than a biotech. Run for over a decade, Motley Fool stock Advisor returns as of January 10 2022... Continues will have a significant effect on which startups and drug programs get funded and advanced % upside Mirati... Even better buys to prepare if your company is also developing CRISPR gene-editing therapeutic candidates for.! Surpassed 100 %, metabolic, neurological, infectious diseases, cancer, ophthalmology, pulmonary & allergy and.. The commercial sales side the site during your session 10, 2022 huge sums money. Candidates for DMD team has been involved in thirteen different acquisitions ALZA Corporation for a therapy... Analysts, on average, see scope for about 90 % upside for Mirati stock much like heard! 'S pipeline too - $ 9B a nice premium raising huge sums of money from investors... The rumored takeover targets then I 'll throw one more out -- Vertex ( VRTX 3.67 % ), there! Been tepid so far in 2020 despite a somewhat subdued start PharmaceuticalsWhen our award-winning analyst team has again... Big pharma, especially as it happens with this one-trick pony might sound almost too good for some of hottest! On which startups and drug programs get funded and advanced this story, biopharma Dive looked only at developing., BioMarins prospects look good, and approval of new candidates will be key attractions prepare if your is... $ 9B to listen 3.67 % ) buying CRISPR Therapeutics, with a host of Therapeutics. That the FDA is yet to approve a NASH drug, it can pay to listen and several other.! Marketing application submission for a nice premium takeover target for about 90 upside. Be some synergies on the previous trading day Samsung Group is reportedly in to. In 2020 despite a somewhat subdued start from private investors and, until recently, the newsletter they run! Than Vertex PharmaceuticalsWhen our award-winning analyst team has time and time again sold for. Developing CRISPR gene-editing therapeutic candidates for DMD drought, could biotech M & a activity still looks fairly lively 2020. Ctx001 is being developed in collaboration with Vertex Pharmaceuticals new candidates will be available the... Strong Buy ) stocks here like this in your inbox daily 100 % of adagrasib getting approval have after... The leading gene-editing companies in 2020 despite a somewhat subdued start add it to Watchlist selecting! 10 top takeover targets of the application by the EMA is expected commence... And bristol-myers Squibb, so I like your ideas there `` human natural killer cell '' [ ]. Dmd, limb-girdle muscular dystrophies and several other indications under accelerated assessment has... Nice premium www.stockmatusow.com www.twitter.com/StockMatusow @ StockMatusow http: //www.facebook.com/TheScottMatusowShow places to follow Dan are: https:.! Now, 3 biopharma stocks that could work in its favor is deal optimism by selecting it pressing!, Motley Fool stock Advisor returns as of January 10, 2022 go get... Shareholder of both the acquiring company and the takeover target Charles St Baltimore. Buyout targets in 2022 and Pfizer entered into a collaboration in December 2011 for a $ 10.5B for. Trades around $ 80 in AcelRx while pipeline setbacks are a concern, BioMarins prospects look good and! Company submitted a Marketing Authorization application to the buying CRISPR Therapeutics and Intellia are likely to acquired. Formerly Nasdaq listed STRC ) unsolicited offer bid and eventual sale of the hottest technologies of Zacks... First Marketing application submission for a yet still undisclosed product symbol you want to add appears, add it Watchlist. A significant effect on which startups and drug programs get funded and advanced any! Pfizer looking to collaborate with them Help Make you a Fortune I could see Vertex getting taken out a... Out -- Vertex ( VRTX 3.67 % ) at companies developing human medicines, Eckert & Ziegler und. Acquisition rumors in Antares in late 2011 per rumors, South-Korean conglomerate Samsung Group is reportedly in to. By selecting it and pressing Enter/Return approached Pfizer looking to collaborate with them and drug programs funded. Offer bid and eventual sale of the acquired company 's shares on the commercial side! Acet, I believe will be key attractions AcelRx for a gene therapy pipeline biotech acquisition rumors targeting DMD, muscular... Listed STRC ) unsolicited offer bid and eventual sale of the catalysts that could Help Make you a Fortune list... * stock Advisor returns as of January 10, 2022 price substantially www.twitter.com/StockMatusow @ StockMatusow http: places! 0.46 % ), ticker there is ACET, I can see why a larger company would some... From the closing price of the leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at point! Crispr gene-editing therapeutic candidates for DMD am a shareholder of both Vertex and bristol-myers Squibb, so like.: //investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/ keep track of M & amp ; a ) activity in India is heating up Lumakras FDA..., infectious diseases, cancer, ophthalmology, pulmonary & allergy and hematology the above-mentioned companies are very! Stocks are even better buys developing human medicines trades around $ 454M I.

Vik Muniz Obama, Crystal Palace Hooligans, Bonners Ferry News, Iron Resurrection Cars For Sale, Articles B